SPOTLIGHT -
EP. 1: Goals of Therapy for Symptomatic Myeloma
EP. 2: MRD Negativity in Multiple Myeloma
EP. 3: Risk Stratification for Myeloma
EP. 4: Optimal Timing for Transplantation in Myeloma
EP. 5: Maintenance Therapy for Multiple Myeloma
EP. 6: Antibodies for Relapsed/ Refractory Multiple Myeloma
EP. 7: Continuing IMiD Therapy after Myeloma Relapse
EP. 8: Sequencing Therapies in Multiple Myeloma
EP. 9: Immunotherapy for Multiple Myeloma
EP. 10: CAR T-Cell Therapy for Multiple Myeloma
EP. 11: Emerging Agents for Multiple Myeloma
EP. 12: Future Directions in Multiple Myeloma
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
